What is Amphastar Pharmaceuticals's market cap?

Amphastar Pharmaceuticals (AMPH) has a market capitalization of $845.7M and trades on NASDAQ.

What is Amphastar Pharmaceuticals's revenue and profitability?

Amphastar Pharmaceuticals generated $720.5M in trailing twelve-month revenue with net income of $79.2M, representing a net margin of 11.0%. Gross margin stands at 47.3%, with free cash flow of $135.2M. These figures are based on the Q1 2026 filing.

Who are Amphastar Pharmaceuticals's competitors?

Amphastar Pharmaceuticals's key competitors include Viatris Inc., Pfizer, Inc., Aquestive Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Amphastar Pharmaceuticals partner with?

Amphastar Pharmaceuticals's notable partners include Eli Lilly & Company, McKesson, Cencora, and others.

What subsidiaries does Amphastar Pharmaceuticals have?

Amphastar Pharmaceuticals's subsidiaries include Amphastar Nanjing Pharmaceuticals (ANP).

Where is Amphastar Pharmaceuticals headquartered?

Amphastar Pharmaceuticals is headquartered in United States of America and employs approximately 1,761 people. It has been publicly traded since 2014.

Amphastar Pharmaceuticals

AMPH

Market cap

$845.7M-15.9%

Revenue$720.5M-1.4%

Net income$79.2M-44.1%

Free cash flow$135.2M-10.0%

EPS (diluted)$1.66-39.9%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$171.2MMiss by $2.3M EPS$0.42Miss by $0.28

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$179.9M

EPS estimate$0.66

Financials

Q1 2026

Income statement

See full

Revenue$171.2M+0.4%

Gross profit$70.3M-17.5%

Operating income$13.6M-63.5%

Net income$6.4M-74.6%

EPS (diluted)$0.14-72.5%

Balance sheet

See full

Cash & equivalents$170.9M-6.5%

Total debt$686.6M+5.2%

Total assets$1.6B+1.3%

Cash flow

See full

Operating cash flow$47.8M+36.4%

CapEx$9.5M-11.1%

Free cash flow$38.3M+57.2%

Valuation & ratios

Valuation

See full

Market cap$845.7M-15.9%

Enterprise value$1.36B-10.2%

P/E10.7×+2.9×

P/S1.2×-0.3×

Profitability

See full

Gross margin47.3%-3.2pp

Operating margin16.2%-10.4pp

Net margin11%-8.4pp

FCF margin18.8%-1.8pp

Returns & leverage

See full

Current ratio3.9×+0.9×

Segments

By geography

See full

US$159.0M-2.2%

FR$9.6M+22.8%

CN$2.5M+2,964%

By segment

See full

Finished Pharmaceutical Products$171.2M+0.4%

Competitors

By market cap

Pfizer$140.61B+1.7%

Viatris$20.5B+89.0%

AptarGroup$8.5B-18.8%

Amneal Pharmaceuticals, Inc.$5.8B+126%

Opko Health$936.3M-12.5%

AMP

Amphastar Pharmaceuticals$845.7M-19.3%

Aquestive Therapeutics, Inc.$468.0M+17.8%

SCN

Scienture Holdings, Inc.$14.9M-43.4%

By revenue growth

AptarGroup+9.0%

Amneal Pharmaceuticals, Inc.+7.6%

Viatris+1.6%

Pfizer+1.4%

AMP

Amphastar Pharmaceuticals-1.4%

Aquestive Therapeutics, Inc.-7.3%

Opko Health-11.5%

By net margin

Pfizer15.65%+6.3pp

AMP

Amphastar Pharmaceuticals11.0%-8.4pp

AptarGroup9.98%-0.4pp

Amneal Pharmaceuticals, Inc.4.01%+4.5pp

Viatris-2.04%+24.4pp

Opko Health-12.4%+14.3pp

Aquestive Therapeutics, Inc.-137.08%-37.1pp

Profile

Amphastar Pharmaceuticals is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of technically challenging generic and proprietary injectable, inhalation, and intranasal products. The company focuses on high-barrier-to-entry medications, including complex molecules, peptides, and proteins, while maintaining a vertically integrated supply chain through its own active pharmaceutical ingredient (API) production. Its core value proposition lies in its ability to produce bioequivalent versions of complex drugs and innovative delivery systems for critical care and chronic conditions.

Competitive position

A leading player in complex generics and specialty injectables with a focus on products with high technical barriers to entry and vertical integration.

GeographiesUnited States, France, China

Customer segmentsHealthcare Providers, Wholesalers, Retail Consumers

Business modelManufacturing, Research and Development, B2B, B2C

SuppliersAnimal-derived raw materials, Hydrofluorocarbons (HFCs), Specialized chemical suppliers, Contract Manufacturing Organizations (CMOs)

CustomersMcKesson, Cencora, Cardinal Health, Group Purchasing Organizations (GPOs)

CountryUnited States of America

Listed2014

Employees1.8K

CEOYongfeng Zhang

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websiteamphastar.com

FilingsSEC EDGAR

Ask your AI about Amphastar Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amphastar Pharmaceuticals's market cap?: Amphastar Pharmaceuticals (AMPH) has a market capitalization of $845.7M and trades on NASDAQ.
What is Amphastar Pharmaceuticals's revenue and profitability?: Amphastar Pharmaceuticals generated $720.5M in trailing twelve-month revenue with net income of $79.2M, representing a net margin of 11.0%. Gross margin stands at 47.3%, with free cash flow of $135.2M. These figures are based on the Q1 2026 filing.
Who are Amphastar Pharmaceuticals's competitors?: Amphastar Pharmaceuticals's key competitors include Viatris Inc., Pfizer, Inc., Aquestive Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Amphastar Pharmaceuticals partner with?: Amphastar Pharmaceuticals's notable partners include Eli Lilly & Company, McKesson, Cencora, and others.
What subsidiaries does Amphastar Pharmaceuticals have?: Amphastar Pharmaceuticals's subsidiaries include Amphastar Nanjing Pharmaceuticals (ANP).
Where is Amphastar Pharmaceuticals headquartered?: Amphastar Pharmaceuticals is headquartered in United States of America and employs approximately 1,761 people. It has been publicly traded since 2014.